Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma.
Standard
Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma. / Deutsch, Lena; Elson, F; Quaas, Alexander; Gawad, Karim A.; Izbicki, Jakob R.
In: ANTICANCER RES, Vol. 27, No. 4, 4, 2007, p. 2897-2902.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma.
AU - Deutsch, Lena
AU - Elson, F
AU - Quaas, Alexander
AU - Gawad, Karim A.
AU - Izbicki, Jakob R.
PY - 2007
Y1 - 2007
N2 - BACKGROUND: Pulmonary metastasectomy in soft tissue sarcoma (STS) can lead to long-term survival. The aim of our study was to report on prognostic factors and the value of repeat resection in recurrent disease. PATIENTS AND METHODS: Seventy-eight pulmonary metastasectomies were performed on 42 STS patients from 1990 to 2005. Overall survival time and 3-year survival rate were evaluated. Subgroup analysis was performed on age, primary tumor stage, histological type and grade, occurrence and recurrence pattern, systemic treatment and number of resections. RESULTS: The 3-year actuarial survival rate was 31%. Primary tumor grade and repeat resections were shown to be independent prognostic factors for survival. CONCLUSION: Patients with repeat resections due to recurrent metastasis show a significantly better prognosis than those with only one resection. Thus, lacking randomised controlled data of the natural course of patients with unresected lung metastases to compare these results, metastasectomy in STS patients is also recommended in recurrent disease.
AB - BACKGROUND: Pulmonary metastasectomy in soft tissue sarcoma (STS) can lead to long-term survival. The aim of our study was to report on prognostic factors and the value of repeat resection in recurrent disease. PATIENTS AND METHODS: Seventy-eight pulmonary metastasectomies were performed on 42 STS patients from 1990 to 2005. Overall survival time and 3-year survival rate were evaluated. Subgroup analysis was performed on age, primary tumor stage, histological type and grade, occurrence and recurrence pattern, systemic treatment and number of resections. RESULTS: The 3-year actuarial survival rate was 31%. Primary tumor grade and repeat resections were shown to be independent prognostic factors for survival. CONCLUSION: Patients with repeat resections due to recurrent metastasis show a significantly better prognosis than those with only one resection. Thus, lacking randomised controlled data of the natural course of patients with unresected lung metastases to compare these results, metastasectomy in STS patients is also recommended in recurrent disease.
M3 - SCORING: Zeitschriftenaufsatz
VL - 27
SP - 2897
EP - 2902
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 4
M1 - 4
ER -